MedTrace Logo

Treatment of Mild Vascular Cognitive Impairment With Yangxue Qingnao Pill

NCT04958512 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-07-12

No results posted yet for this study

Summary

In this study, the effectiveness of vascular cognitive impairment was compared among the three groups, namely, the xidezhen group, the Yangxue Qingnao pill group and the placebo group

Conditions

  • Cerebrovascular Diseases

Interventions

DRUG

Yangxue Qingnao pill

The treatment group (20 cases) was treated with Yangxue Qingnao pill (2.5g / time, 3 times / day, orally for 6 months

DRUG

Hydergotoxine mesylate tablets

The control group (n = 20) was treated with hidezhen 3 mg per day before meals for 6 months

OTHER

blank control group

There were 20 cases in the blank control group.Outpatient consultation at any time was prescribed.

Sponsors & Collaborators

  • Beijing Hospital

    collaborator OTHER_GOV

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Dongsheng Fan · Peking University Third Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-30
Primary Completion
2018-01-31
Completion
2018-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04958512 on ClinicalTrials.gov